Provided by Tiger Trade Technology Pte. Ltd.

Stoke Therapeutics, Inc.

32.32
+0.03000.09%
Post-market: 32.320.00000.00%16:53 EDT
Volume:562.29K
Turnover:18.18M
Market Cap:2.09B
PE:-9.70
High:32.76
Open:32.29
Low:31.16
Close:32.29
52wk High:40.22
52wk Low:18.00
Shares:64.53M
Float Shares:49.01M
Volume Ratio:0.54
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3325
EPS(LYR):-0.1163
ROE:-61.10%
ROA:-35.87%
PB:6.04
PE(LYR):-277.99

Loading ...

Press Release: Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates

Dow Jones
·
Jul 28

Stoke Therapeutics Schedules Webcast, Call on Q2 Business and Financial Update

Reuters
·
Jul 28

Can Stoke Therapeutics (STOK) Be A Bargain As Its New CSO Reshapes The Story?

Simply Wall St.
·
Jul 22

Stoke Therapeutics Chief Scientific Officer Thomas Mccauley Files Initial Beneficial Ownership Statement

Reuters
·
Jul 18

Stoke Therapeutics Grants CSO Mccauley Options for 225,000 Shares at $29.91 Each

Reuters
·
Jul 17

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and Oncolytics Biotech (ONCY)

TIPRANKS
·
Jul 14

Stoke Therapeutics Names Thomas Mccauley Chief Scientific Officer

Reuters
·
Jul 13

Stoke Therapeutics Appoints Thomas Mccauley, Ph.d., as Chief Scientific Officer

THOMSON REUTERS
·
Jul 13

Stoke Therapeutics Initiated at Buy by Goldman Sachs

Dow Jones
·
Jul 13

Stoke Therapeutics initiated with a Buy at Goldman Sachs

TIPRANKS
·
Jul 13

Can Stoke Therapeutics (STOK) Justify Its Valuation Following The Phase 3 EMPEROR Update?

Simply Wall St.
·
Jul 10

Analysts Are Bullish on Top Healthcare Stocks: Urogen Pharma (URGN), Stoke Therapeutics (STOK)

TIPRANKS
·
Jul 09

Stoke Therapeutics CMO Barry Ticho Disposes of Common Shares Worth $235,889.32

Reuters
·
Jul 07

Stoke Therapeutics (STOK) Receives a Buy from Jefferies

TIPRANKS
·
Jul 06

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients into the Phase 3 Emperor Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Reuters
·
Jul 06

Stoke Therapeutics (STOK) Receives a Buy from Jefferies

TIPRANKS
·
Jul 02

Stoke Therapeutics Completes Enrollment in Phase 3 Emperor Trial of Dravet Drug Zorevunersen

Reuters
·
Jun 30

Stoke Therapeutics - no Patients Have Discontinued Treatment in Phase 3 Emperor Study

THOMSON REUTERS
·
Jun 30

Stoke Therapeutics - Phase 3 Data Readout Anticipated in Q3 2027, to Complete Nda Submission in H2 2027

THOMSON REUTERS
·
Jun 30

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients into the Phase 3 Emperor Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

THOMSON REUTERS
·
Jun 30